All Stories

  1. Tyrosine kinase inhibitor, masitinib, limits neuronal damage, as measured by serum neurofilament light chain concentration in a model of neuroimmune-driven neurodegenerative disease

    Article • PLOS One, May 2025, PLOS

    olivier Hermine

  2. Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design

    Article • European Respiratory Journal, July 2022, European Respiratory Society (ERS)

    olivier Hermine, MD, PhD Pierre-Louis Tharaux

  3. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group

    Article • European Respiratory Journal, February 2022, European Respiratory Society (ERS)

    olivier Hermine, MD, PhD Pierre-Louis Tharaux

  4. Recent advances in the understanding and therapeutic management of mastocytosis

    Article • F1000Research, November 2019, Faculty of 1000, Ltd.

    olivier Hermine

  5. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

    Article • Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, July 2019, Taylor & Francis

    olivier Hermine

  6. Human CD4- invariant NKT lymphocytes regulate graft versus host disease

    Article • OncoImmunology, June 2018, Taylor & Francis

    olivier Hermine

  7. Clinical potential of midostaurin in advanced systemic mastocytosis

    Article • Blood and Lymphatic Cancer Targets and Therapy, May 2017, Dove Medical Press

    Olivier Lortholary , olivier Hermine